Klinisch orientierter Schwerpunkt
FB 04 - Universitätsmedizin / Johannes Gutenberg-Universität Mainz
Ganten, Tom M.; Stauber, Rudolf E.; Schott, Eckardt et al.
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT StudyCLINICAL CANCER RESEARCH. Bd. 23. H. 19. 2017 S. 5720-5728
Hagemann, Jan; Jacobi, Christian; Hahn, Moritz et al.
Spheroid-based 3D Cell Cultures Enable Personalized Therapy Testing and Drug Discovery in Head and Neck CancerANTICANCER RESEARCH. Bd. 37. H. 5. 2017 S. 2201-2210
Hagemann, Jan; Jacobi, Christian; Hahn, Moritz et al.
Spheroid-based 3D Cell Cultures Enable Personalized Therapy Testing and Drug Discovery in Head and Neck Cancer (vol 37, pg 2201, 2017)ANTICANCER RESEARCH. Bd. 37. H. 7. 2017 S. 3981-3981
Hagemann, Jan; Jacobi, Christian; Hahn, Moritz et al.
Spheroid-based 3D Cell Cultures Enable Personalized Therapy Testing and Drug Discovery in Head and Neck Cancer (vol 37, pg 2201, 2017)ANTICANCER RESEARCH. Bd. 37. H. 12. 2017 S. 7308-7308
Tsaur, I.; Becker, C.; Thelen, P. et al.
Splice variant AR-V7. Is it time for its routine use as a predictive marker in prostate cancer?UROLOGE. Bd. 56. H. 9. 2017 S. 1164-1167
Heimes, A-S.; Madjar, K.; Edlund, K. et al.
Subtype-specific prognostic impact of different immune signatures in node-negative breast cancerBREAST CANCER RESEARCH AND TREATMENT. Bd. 165. H. 2. 2017 S. 293-300
Juengel, Eva; Euler, Stephanie; Maxeiner, Sebastian et al.
Sulforaphane as an adjunctive to everolimus counteracts everolimus resistance in renal cancer cell linesPHYTOMEDICINE. Bd. 27. 2017 S. 1-7
Schmidt, M
Supportivtherapie in der Gynäkologischen OnkologieGynäkologische Onkologie. Schattauer GmbH Verlag für Medizin und Naturwissenschaften 2017
Sagheb, Keyvan; Manz, Asina; Albrich, Stefan B. et al.
Supraclavicular Metastases from Distant Primary Solid Tumours: A Retrospective Study of 41 YearsJOURNAL OF MAXILLOFACIAL & ORAL SURGERY. Bd. 16. H. 2. 2017 S. 152-157
Woerns, M. -A.; Merle, P.; Granito, A. et al.
Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placeboONCOLOGY RESEARCH AND TREATMENT. Bd. 40. 2017 S. 161-162